INKTMiNK Therapeutics Inc. Common Stock
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell ther…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript Net loss narrowed to $3.1 million as Phase 2 trial for agenT-797 advances in Ukraine. | ||
 MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of MiNK Therapeutics, Inc.'s Q2 2026 earnings call | ||
MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ... MiNK Therapeutics reports encouraging initial data from its ARDS study, narrows net loss, and expands international access programs despite a tight cash position. | ||
 MiNK Therapeutics Q2 Earnings Call Highlights MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026. The company also lau | ||
 Here's Why You Should Add INKT Stock to Your Portfolio Now MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline. | ||